Brickell Biotech Inc
Change company Symbol lookup
Select an option...
BBI Brickell Biotech Inc
VTOL Bristow Group Inc
VTRS Viatris Inc
MSFT Microsoft Corp
NTB Bank of N T Butterfield & Son Ltd
CHN China Fund, Inc.
IGR CBRE Global Real Estate Income Fund
SURRY Sun Art Retail Group Ltd
VPV Invesco Pennsylvania Value Municipal Income Trust
HLBZ Helbiz Inc
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Brickell Biotech, Inc. is a clinical-stage pharmaceutical company engaged in developing prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases. The Company’s pipeline combines several development-stage candidates and a cutting-edge platform with autoimmune and inflammatory disorders program for the treatment of primary axillary hyperhidrosis. Its products include Cialis, Taltz, Gemzar, Prozac, Cymbalta and Juvederm. Its lead development-stage program, BBI-02, is a Phase I ready, highly selective, and orally bioavailable DYRK1A inhibitor that has demonstrated in various preclinical models, including atopic dermatitis and rheumatoid arthritis. BBI-10, the Company’s lead early-stage STING inhibitor candidate, is a novel, potent, and orally available covalent STING inhibitor that specifically targets the palmitoylation site of STING, which allows to inhibit both wild-type STING and gain-of-function mutants.

Premarket

Last Trade
Delayed
$3.50
Change Since Close

Change Since Close

Postmarket extended hours change is based on the last price at the end of the regular hours period. Premarket extended hours change is based on the day's regular session close.

0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$3.50
Day's Change
0.00 (0.00%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
3,011

10-day average volume:
472,875
3,011
Historical quotes & splits

NVIDIA Corp. Stock Underperforms Thursday When Compared To Competitors

5:12 pm ET June 9, 2022 (MarketWatch)
Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of NVIDIA Corp. (NVDA) slipped 3.22% to $180.48 Thursday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index falling 2.38% to 4,017.82 and Dow Jones Industrial Average falling 1.94% to 32,272.79. This was the stock's second consecutive day of losses. NVIDIA Corp. closed $165.99 short of its 52-week high ($346.47), which the company achieved on November 22nd.

The stock underperformed when compared to some of its competitors Thursday, as Microsoft Corp. (MSFT) fell 2.08% to $264.79, Intel Corp. (INTC) fell 2.96% to $40.01, and Texas Instruments Inc. (TXN) fell 2.29% to $161.58. Trading volume (39.4 M) remained 19.4 million below its 50-day average volume of 58.8 M.

Data source: Dow Jones Market Data, FactSet. Data compiled June 9, 2022.

(END) Dow Jones Newswires

June 09, 2022 17:12 ET (21:12 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.

3rd Party Research Disclosure